Baker Bros. Advisors Adds $4M in Design Therapeutics, Inc. ($DSGN)
Key Points
- Baker Bros. Advisors changed its Design Therapeutics, Inc. ($DSGN) stake by 15.8% last quarter, boosting to 2,585,978 shares worth $28.37 million.
- Wall Street's consensus rating on $DSGN is Strong Buy and an average price target of $21.00.
- $DSGN last traded around $10.97.
Baker Bros. Advisors increased its position in Design Therapeutics, Inc. ($DSGN) by 15.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,585,978 shares of Design Therapeutics, Inc. after buying 352,879 shares during the quarter. Baker Bros. Advisors's holdings in Design Therapeutics, Inc. were worth $28.37 million as of its most recent filing.
Design Therapeutics, Inc. ($DSGN) Stock
Design Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.